Priority Review for Lilly's olaratumab

Eli Lilly and Co. (NYSE:LLY) said FDA accepted and granted Priority Review to a BLA for olaratumab ( LY3012207) in combination with doxorubicin to treat advanced soft tissue sarcoma (STS) that cannot be treated with radiotherapy or surgery. Lilly spokesperson Karen Glowacki declined to disclose its PDUFA date.

Data from a Phase Ib/II study presented at last year's American Society of Clinical Oncology meeting showed the combo met its primary endpoint of improving progression-free survival vs. doxorubicin alone to treat advanced STS. The combo also significantly improved overall survival vs. doxorubicin. ...